hope medicine building for hmi-115 for treatment of hair loss


Learn About the Promising Results from Hope Medicines Phase 1B Trials

In the ever-evolving landscape of biopharmaceutical innovation, Hope Medicine Inc. (HopeMed) emerges as a beacon of progress, spearheading groundbreaking advancements in the treatment of challenging medical conditions. With a steadfast commitment to pioneering novel therapies, the company has garnered significant attention with its recent milestone announcement. The U.S. Food and Drug Administration’s (FDA) approval of HopeMed’s Investigational New Drug (IND) application for phase II study marks a pivotal moment in the journey towards transformative treatments. This approval sets the stage for the evaluation of HMI-115, a revolutionary monoclonal antibody drug designed to address androgenetic alopecia, a condition affecting millions worldwide. Through strategic partnerships and a relentless pursuit of scientific excellence, HopeMed stands poised to redefine the treatment landscape, offering hope and healing to patients in need.


Hope Medicine Inc. (HopeMed), an innovative biopharmaceutical company in the clinical stage, has recently made a significant announcement: the U.S. Food and Drug Administration (FDA) has granted approval for its Investigational New Drug (IND) application for phase II study. This study aims to evaluate HMI-115, a pioneering monoclonal antibody drug designed to address androgenetic alopecia, also known as male and female pattern hair loss. Remarkably, in 2021, HMI-115 had already received FDA Clearance of its IND Application for Phase II clinical trials targeting endometriosis.

Back in April 2019, HopeMed forged a worldwide exclusive license agreement with Bayer AG, focusing on the development and commercialization of a human monoclonal antibody directed at the PRL receptor. This antibody aims to tackle male and female pattern hair loss, endometriosis, and other chronic conditions characterized by dysregulated prolactin (PRL) signaling. Impressively, the antibody has demonstrated exceptional qualities in animal models, including NHP models, and human safety studies. Notably, both its treatments for endometriosis and androgenetic alopecia have received FDA approval for Phase II clinical trials.

The Phase II clinical trial of HMI-115 targeting endometriosis has already commenced patient enrollment in the U.S. as of the end of 2021. Meanwhile, the Phase II clinical trial for the treatment of androgenetic alopecia is slated to be an international multi-center endeavor. It will be a randomized, double-blind, placebo-controlled study, with planned sites in the United States, Australia, and other countries.

Dr. Henri Doods, CEO of HopeMed, expressed pride in the FDA’s approval of their second IND, marking a significant milestone for the company. This approval represents a crucial step forward in their mission to introduce First-in-Class and highly differentiated products to patients. Dr. Doods highlighted the urgent need for improved treatment options in both endometriosis and alopecia, emphasizing the team’s dedication to advancing innovative therapeutic solutions globally. The rapid success of securing two IND approvals underscores HopeMed’s commitment to expanding its research and development efforts to benefit patients worldwide.


Hope Medicine Inc. is a leading clinical-stage biopharmaceutical company headquartered in Beijing, with additional research facilities and offices in Shanghai and Nanjing, China. Founded on the profound insights of translational medicine and decades of research findings from Professor Rui-Ping Xiao’s laboratory at Peking University’s College of Future Technology, the company is dedicated to advancing healthcare through cutting-edge scientific research. With a primary focus on enhancing quality of life, HopeMed is steadfast in its pursuit of developing and commercializing pioneering medications for prevalent and severe diseases that pose significant threats to human well-being.

Hope medicine logo for phase 2 trials of HMI-115 HopeMed

In May 2021, the company secured round B financing, further bolstering its efforts, following a groundbreaking worldwide exclusive license agreement with Bayer AG for the development and commercialization of HMI-115. Additionally, leveraging the breakthrough research of Professor Xiao at Peking University’s Institute of Molecular Medicine (IMM), HopeMed has established a diverse research portfolio. This collaborative endeavor includes the establishment of a joint research laboratory with a strong translational emphasis, fostering a continuous stream of innovative discoveries in the early stages of development.


Androgenetic alopecia, commonly known as male or female pattern baldness, is a prevalent form of hair loss characterized by a progressive thinning of the hair follicles, typically in a predictable pattern. In men, this often manifests as a receding hairline and balding at the crown, whereas in women, it tends to result in diffuse hair thinning across the scalp. This condition is primarily influenced by genetic factors and the hormone dihydrotestosterone (DHT), which shortens the hair growth cycle, leading to miniaturization of hair follicles and eventual hair loss. While androgenetic alopecia is not typically associated with underlying medical conditions, it can have significant psychosocial impacts, affecting self-esteem and quality of life. Treatment options may include medications such as minoxidil or finasteride, as well as surgical interventions like hair transplantation, aimed at slowing down hair loss and promoting hair regrowth.


Endometriosis is a chronic and often debilitating medical condition characterized by the abnormal growth of endometrial-like tissue outside the uterus. Normally, the endometrium, a tissue lining the inside of the uterus, thickens and sheds during each menstrual cycle. However, in individuals with endometriosis, this tissue can implant and grow on other pelvic organs, such as the ovaries, fallopian tubes, and the lining of the pelvis. This misplaced tissue responds to hormonal changes during the menstrual cycle, leading to inflammation, scarring, and the formation of painful adhesions.

The symptoms of endometriosis can vary widely and may include pelvic pain, particularly during menstruation, intercourse, or bowel movements, as well as heavy menstrual bleeding, infertility, and fatigue. The severity of symptoms does not always correlate with the extent of the condition, and diagnosis may be delayed due to the overlap of symptoms with other gynecological disorders. While the exact cause of endometriosis remains unclear, factors such as hormonal imbalances, immune dysfunction, and genetic predisposition are thought to contribute to its development. Treatment options for endometriosis aim to alleviate symptoms and may include pain management, hormonal therapies to suppress menstruation, and surgical interventions to remove endometrial lesions and scar tissue.


Hope Medicine Inc. (HopeMed) stands at the forefront of biopharmaceutical innovation with its recent FDA approval of the Investigational New Drug (IND) application for phase II study. This milestone represents a significant step forward in the development of HMI-115, a pioneering monoclonal antibody drug designed to address androgenetic alopecia and endometriosis. Through strategic partnerships and groundbreaking research, HopeMed has demonstrated its commitment to advancing novel therapies for conditions with significant unmet medical needs. The commencement of phase II clinical trials for both endometriosis and androgenetic alopecia reflects the company’s dedication to bringing First-in-Class treatments to patients worldwide. Led by CEO Dr. Henri Doods, HopeMed continues to drive innovation in the biopharmaceutical industry, with a focus on improving the lives of individuals affected by chronic diseases. As the company expands its research and development efforts, the future holds promise for groundbreaking advancements in therapeutic solutions, paving the way for enhanced patient outcomes and improved quality of life globally.


Hair loss products in a row

Leave a Comment

Your email address will not be published. Required fields are marked *